Roadmap to 2030 for Drug Evaluation in Older Adults.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
23
03
2021
accepted:
04
10
2021
pubmed:
17
10
2021
medline:
22
7
2022
entrez:
16
10
2021
Statut:
ppublish
Résumé
Changes that accompany older age can alter the pharmacokinetics (PK), pharmacodynamics (PD), and likelihood of adverse effects (AEs) of a drug. However, older adults, especially the oldest or those with multiple chronic health conditions, polypharmacy, or frailty, are often under-represented in clinical trials of new drugs. Deficits in the current conduct of clinical evaluation of drugs for older adults and potential steps to fill those knowledge gaps are presented in this communication. The most important step is to increase clinical trial enrollment of older adults who are representative of the target treatment population. Unnecessary eligibility criteria should be eliminated. Physical and financial barriers to participation should be removed. Incentives could be created for inclusion of older adults. Enrollment goals should be established based on intended treatment indications, prevalence of the condition, and feasibility. Relevant clinical pharmacology data need to be obtained early enough to guide dosing and reduce risk for participation of older adults. Relevant PK and PD data as well as patient-centered outcomes should be measured during trials. Trial data should be analyzed for differences in PK, PD, effectiveness, and safety arising from differences in age or from the presence of conditions common in older adults. Postmarket evaluations with real-world evidence and drug labeling updates throughout the product lifecycle reflecting new knowledge are also needed. A comprehensive plan is needed to ensure adequate evaluation of the safety and effectiveness of drugs in older adults.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210-223Subventions
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.
Références
US Food and Drug Administration (FDA). WORKSHOP: Roadmap to 2030 for new drug evaluation in older adults <https://www.fda.gov/drugs/news-events-human-drugs/roadmap-2030-new-drug-evaluation-older-adults-03232021-03232021> (2021). Accessed July 16, 2021.
United States Census Bureau. The graying of America: more older adults than kids by 2035 <https://www.census.gov/library/stories/2018/03/graying-america.html> (2018). Accessed June 25, 2021.
Donohoe, K.L., Price, E.T., Gendron, T.L. & Slattum, P.W. Geriatrics: the aging process in humans and its effects on physiology. In Pharmacotherapy: A Pathophysiologic Approach, 11e (eds. DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., & Ellingrod, V.). (McGraw-Hill Education, New York, NY, 2020).
Fried, L.P. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146-M156 (2001).
Mitnitski, A. et al. Age-related frailty and its association with biological markers of ageing. BMC Med. 13, 161 (2015).
Bandeen-Roche, K. et al. Frailty in older adults: a nationally representative profile in the United States. J. Gerontol. A Biol. Sci. Med. Sci. 70, 1427-1434 (2015).
National Council on Aging. Get the facts on healthy aging <https://www.ncoa.org/article/get-the-facts-on-healthy-aging> (2021). Accessed June 28, 2021.
Lown Institute. Medication overload: America’s other drug problem; how the drive to prescribe is harming older adults <https://lowninstitute.org/wp-content/uploads/2019/08/medication-overload-lown-web.pdf> (2019). Accessed June 28, 2021.
Gutiérrez-Valencia, M., Izquierdo, M., Cesari, M., Casas-Herrero, Á ., Inzitari, M. & Martínez-Velilla, N. The relationship between frailty and polypharmacy in older people: A systematic review. Br. J. Clin. Pharmacol. 84, 1432-1444 (2018).
Mach, J. et al. Chronic polypharmacy with increasing drug burden index exacerbates frailty and impairs physical function, with effects attenuated by deprescribing, in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 76, 1010-1018 (2021).
Ferrucci, L. & Kuchel, G.A. Heterogeneity of aging: individual risk factors, mechanisms, patient priorities, and outcomes. J. Am. Geriatr. Soc. 69, 610-612 (2021).
21 C.F.R. § 314.50(d)(5)(v) (1986); 21 C.F.R. § 314.50(d)(5)(v) <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.50> (2021).
New Drug and Antibiotic Regulations, Final Rule, 50 Fed. Reg. 7452, 7496 (February 22, 1985)(to be codified at 21 C.F.R. pt. 314) <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/new-drug-and-antibiotic-regulations-part-3> (1985).
US FDA. GUIDANCE DOCUMENT: Format and Content of the Clinical and Statistical Sections of an Application <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-and-content-clinical-and-statistical-sections-application> (1988). Accessed July 16, 2021.
US FDA. GUIDANCE DOCUMENT: study of drugs likely to be used in the elderly <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072048.pdf> (1989). Accessed June 26, 2021.
US FDA. GUIDANCE DOCUMENT: E7 studies in support of special populations: geriatrics <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073131.pdf> (1994). Accessed June 26, 2021.
Cerreta, F., Temple, R., Asahina, Y. & Connaire, C. Regulatory activities to address the needs of older patients. J. Nutr. Health Aging 19, 232-233 (2015).
GUIDANCE DOCUMENT: E7 studies in support of special populations; geriatrics; questions and answers <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics-questions-and-answers> (2012). Accessed June 26, 2021.
US FDA. GUIDANCE DOCUMENT: enhancing the diversity of clinical trial populations - eligibility criteria, enrollment practices, and trial designs guidance for industry <https://www.fda.gov/media/127712/download> (2020). Accessed June 26, 2021.
U.S. Government Publishing Office. 62 FR 45313 - Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Addition of “Geriatric Use” Subsection in the Labeling <https://www.govinfo.gov/app/details/FR-1997-08-27/97-22701/summary> (1997). Accessed June 26, 2021.
Final Rule. 63 FR 6854. 21 CFR 312 and 21 CFR 314: Investigational New Drug Applications and New Drug Applications. (Demographic Rule). Fed. Reg. 63, 6854-6862 (1998).
US FDA. Guidance for industry: content and format for geriatric labeling <https://www.fda.gov/media/72141/download> (2001). Accessed June 26, 2021.
US Government. PUBLIC LAW 112-144-JULY 9, 2012 <https://www.govinfo.gov/content/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf> (2012). Accessed July 16, 2021.
US FDA. FDA Report: collection, analysis, and availability of demographic subgroup data for FDA-approved medical products <https://www.fda.gov/files/about%20fda/published/Collection--Analysis--and-Availability-of-Demographic-Subgroup-Data-for-FDA-Approved-Medical-Products.pdf> (2013). Accessed August 31, 2021.
US FDA. FDA report: FDA action plan to enhance the collection and availability of demographic subgroup data <https://www.fda.gov/media/89307/download> (2014). Accessed July 17, 2021.
European Medicines Agency. Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials <https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical_en.pdf> (2018). Accessed June 26, 2021.
US FDA. Draft guidance: inclusion of older adults in cancer clinical trials <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inclusion-older-adults-cancer-clinical-trials> (2020). Accessed July 24, 2021.
US FDA. DRAFT GUIDANCE: geriatric information in human prescription drug and biological product labeling <https://www.fda.gov/media/142162/download> (2020). Accessed June 26, 2021.
Aprahamian, I. & Morley, J.E. Editorial: to drug or not to drug: the geriatrician dilemma of polypharmacy. J. Nutr. Health Aging 24, 809-811 (2020).
Chen, A. et al. Representation of women and minorities in clinical trials for new molecular entities and original therapeutic biologics approved by FDA CDER from 2013 to 2015. J. Womens Health (Larchmt). 27, 418-429 (2018).
Kanesvaran, R., Mohile, S., Soto-Perez-de-Celis, E. & Singh, H. The globalization of geriatric oncology: from data to practice. Am. Soc. Clin. Oncol. Educ. Book 40, 1-9 (2020).
Helfand, B.K.I., Webb, M., Gartaganis, S.L., Fuller, L., Kwon, C.S. & Inouye, S.K. The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019-missing the target. JAMA Intern. Med. 180, 1546-1549 (2020).
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99-111 (2021).
Polack, F.P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603-2615 (2020).
Baden, L.R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403-416 (2021).
Logunov, D.Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671-681 (2021).
US FDA. General considerations for the clinical evaluation of drugs <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-clinical-evaluation-drugs> (1977). Accessed June 26, 2021.
Powell, J.R., Cook, J., Wang, Y., Peck, R. & Weiner, D. Drug dosing recommendations for all patients: a roadmap for change. Clin. Pharmacol. Ther. 109, 65-72 (2021).
World Health Organization. Ageing and health <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health> Accessed June 27, 2021.
National Center for Health Statistics. Centers for disease control and prevention <https://www.cdc.gov/about/organization/cio-orgcharts/nchs.html>. Accessed June 27, 2021.
US FDA. Drug trials snapshots <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots> (2021). Accessed May 14, 2021.
National Archive of Computerized Data on Aging <https://www.icpsr.umich.edu/web/pages/NACDA/index.html> Accessed June 27, 2021.
Virani, S.S. et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 141, e139-e596 (2020).
Rubin, E. Striving for diversity in research studies. N. Engl. J. Med 385, 1429-1430 (2021).
Gauthier, J.M. & Massicotte, A. Statins and their effect on cognition: Let's clear up the confusion. Can. Pharm. J. (Ott). 148, 150-155 (2015).
Montiel-Luque, A. et al. Medication-related factors associated with health-related quality of life in patients older than 65 years with polypharmacy. PLoS One 12, e0171320 (2017).
Furlan, G., Caduff-Janosa, P., Sottosanti, L., Cappello, E., Valdiserra, G. & Tuccori, M. Drug safety in geriatric patients: current status and proposed way forward. Drug Saf. 43, 853-866 (2020).
Wilson, N.M. et al. Associations between drug burden index and falls in older people in residential aged care. J. Am. Geriatr. Soc. 59, 875-880 (2011).
Sargent, L. et al. Anticholinergic drug induced cognitive and physical impairment: results from the InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 75, 995-1002 (2020).
Bowie, M.W. & Slattum, P.W. Pharmacodynamics in older adults: a review. Am. J. Geriatr. Pharmacother. 5, 263-303 (2007).
Trifiro, G. & Spina, E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr. Drug Metab. 12, 611-620 (2011).
Thurmann, P.A. Pharmacodynamics and pharmacokinetics in older adults. Curr. Opin. Anaesthesiol. 33, 109-113 (2020).
Brody, D.J., Kramarow, E.A., Taylor, C.A. & McGuire, L.C. Cognitive performance in adults aged 60 and over: National Health and Nutrition Examination Survey, 2011-2014. Natl. Health Stat. Rep. 126, 1-23 (2019).
Spong, C.Y. & Bianchi, D.W. Improving public health requires inclusion of underrepresented populations in research. JAMA 319, 337-338 (2018).
Shepherd, V., Wood, F., Griffith, R., Sheehan, M. & Hood, K. Protection by exclusion? The (lack of) inclusion of adults who lack capacity to consent to research in clinical trials in the UK. Trials 20, 474 (2019).
Knechel, N.A. The challenges of enrolling older adults into intervention studies. Yale J. Biol. Med. 86, 41-47 (2013).
NIH. A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2) <https://clinicaltrials.gov/ct2/show/NCT04497987> (2020). Accessed July 16, 2021.
DiazGranados, C.A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med. 371, 635-645 (2014).
European Medicines Agency. ICH topic E7: studies in support of special populations: geriatrics, questions and answers <https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-questions-answers-step-5_en.pdf> (2010). Accessed June 27, 2021.
Duke-Margolis Center for Health Policy. Conference: Evaluating Inclusion and Exclusion Criteria in Clinical Trials <https://healthpolicy.duke.edu/events/evaluating-inclusion-and-exclusion-criteria-clinical-trials> (2018). Accessed June 27, 2021.
Sedrak, M.S. et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J. Clin. 71, 78-92 (2021).
Bowling, C.B., Whitson, H.E. & Johnson, T.M. 2nd. The 5Ts: preliminary development of a framework to support inclusion of older adults in research. J. Am. Geriatr. Soc. 67, 342-346 (2019).
The National Academies of Sciences, Engineering and Medicine. Drug research and development for adults across the older age span: a workshop <https://www.nationalacademies.org/our-work/drug-research-and-development-for-adults-across-the-older-age-span-a-workshop> (2021). Accessed June 27, 2021.
US FDA. Draft guidance: core patient-reported outcomes in cancer clinical trials <https://www.fda.gov/media/149994/download> (2021). Accessed June 27, 2021.
US FDA. Guidance document: type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control <https://www.fda.gov/media/135936/download> (2020). Accessed July 16, 2021.
US FDA. Draft guidance: type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control <https://www.fda.gov/media/135936/download> (2020). Accessed July 16, 2021.
Akpan, A. et al. Standard set of health outcome measures for older persons. BMC Geriatr. 18, 36 (2018).
Tinetti, M., Huang, A. & Molnar, F. The geriatrics 5M's: a new way of communicating what we do. J. Am. Geriatr. Soc. 65, 2115 (2017).
Menon-Andersen, D. et al. Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label. Clin. Pharmacol. Ther. 90, 471-474 (2011).
Cuzick, J. Forest plots and the interpretation of subgroups. Lancet 365, 1308 (2005).
US FDA. Reviewer guidance: conducting a clinical safety review of a new product application and preparing a report on the review <https://www.fda.gov/media/71665/download> (2005). Accessed June 27, 2021.
US FDA. FDA's Sentinel Initiative <https://www.fda.gov/safety/fdas-sentinel-initiative> (2019). Accessed August 30, 2021.
US FDA. Assessing the effects of food on drugs in INDs and NDAs - clinical pharmacology considerations <https://www.fda.gov/media/121313/download> (2019). Accessed October 2, 2020.
US FDA. Best practices in drug and biological product postmarket safety surveillance for FDA staff (draft) <https://www.fda.gov/media/130216/download> (2019). Accessed June 27, 2021.
Dave, C.V., Schneeweiss, S., Kim, D., Fralick, M., Tong, A. & Patorno, E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann. Intern. Med. 171, 248-256 (2019).
Graham, D.J. et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am. J. Med. 132, 596-604 e511 (2019).
Khozin, S. et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist 24, 648-656 (2019).
OHDSI. Observational Health Data Sciences and Informatics <https://www.ohdsi.org/> (2021). Accessed July 18, 2021.
Franklin, J.M. et al. When can nonrandomized studies support valid inference regarding effectiveness or safety of new medical treatments? Clin. Pharmacol. Ther. 111, 108-115 (2022)
US FDA. Framework for FDA's real-world evidence program <https://www.fda.gov/media/120060/download> (2018). Accessed October 2, 2020.
Kouladjian O'Donnell, L., Reeve, E., Cumming, A., Scott, I.A. & Hilmer, S.N. Development and dissemination of the national strategic action plan for reducing inappropriate polypharmacy in older Australians. Intern. Med. J. 51, 111-115 (2021).
Portman, R.M., Levy, A.R., Maher, A.J. & Fairclough, S.J. Multi-stakeholder retrospective acceptability of a peer support intervention for exercise referral. Int. J. Environ. Res. Public Health 18, 1720 (2021).
Skolnick, A.H. & Alexander, K.P. Older adults in clinical research and drug development: closing the geriatric gap. Circ. Cardiovasc. Qual. Outcomes 8, 631-633 (2015).
National Institutes of Health. Inclusion across the lifespan workshop <https://grants.nih.gov/sites/default/files/IAL-II-Workshop-Report.pdf> (2020). Accessed June 27, 2021.
Inclusion of Older Adults in Clinical Research 2021 Workshop. Research Centers Collaborative Network, National Institutes on Aging <https://www.rccn-aging.org/inclusion-rccn-workshop> (2021). Accessed August 31, 2021.
Tanaka, S. et al. The dual presence of frailty and locomotive syndrome is associated with a greater decrease in the EQ-5D-5L index. Nagoya J. Med. Sci. 83, 159-167 (2021).
Gurwitz, J.H. The exclusion of older people from participation in cardiovascular trials. Virtual Mentor 16, 365-368 (2014).
US FDA. Drug trials snapshots <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots> (2021). Accessed June 26, 2021.
US FDA. History of FDA guidance on drug evaluation in older adult patients <https://www.fda.gov/media/147956/download> (2021). Accessed September 19, 2021.